RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS SCIE

      Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment

      한글로보기

      https://www.riss.kr/link?id=A106494588

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation.
      However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment.
      번역하기

      Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In add...

      Cancer incidence appears to be increased in both type 1 and type 2 diabetes mellitus (DM). DM represents a risk factor for cancer, particularly hepatocellular, hepatobiliary, pancreas, breast, ovarian, endometrial, and gastrointestinal cancers. In addition, there is evidence showing that DM is associated with increased cancer mortality. Common risk factors such as age, obesity, physical inactivity and smoking may contribute to increased cancer risk in patients with DM. Although the mechanistic process that may link diabetes to cancer is not completely understood yet, biological mechanisms linking DM and cancer are hyperglycemia, hyperinsulinemia, increased bioactivity of insulin-like growth factor 1, oxidative stress, dysregulations of sex hormones, and chronic inflammation.
      However, cancer screening rate is significantly lower in people with DM than that in people without diabetes. Evidence from previous studies suggests that some medications used to treat DM are associated with either increased or reduced risk of cancer. However, there is no strong evidence supporting the association between the use of anti-hyperglycemic medication and specific cancer. In conclusion, all patients with DM should be undergo recommended age- and sex appropriate cancer screenings to promote primary prevention and early detection. Furthermore, cancer should be screened in routine diabetes assessment.

      더보기

      참고문헌 (Reference)

      1 Pearson-Stuttard J, "Worldwide burden of cancer attributable to diabetes and high body-mass index : a comparative risk assessment" 6 : e6-e15, 2018

      2 Burstein HJ, "Use of the peroxisome proliferator-activated receptor(PPAR)gamma ligand troglitazone as treatment for refractory breast cancer : a phase II study" 79 : 391-397, 2003

      3 Noto H, "Unfolding link between diabetes and cancer" 9 : 473-474, 2018

      4 Yu F, "Type 2 diabetes mellitus and risk of colorectal adenoma : a meta-analysis of observational studies" 16 : 642-, 2016

      5 Shlomai G, "Type 2 diabetes mellitus and cancer : the role of pharmacotherapy" 34 : 4261-4269, 2016

      6 Tsilidis KK, "Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies" 350 : g7607-, 2015

      7 Lim D, "Trends in major cancer mortality in Korea, 1983-2012, with a joinpoint analysis" 39 : 939-946, 2015

      8 서민아, "Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2013" 대한암학회 48 (48): 1-10, 2016

      9 Monami M, "Thiazolidinediones and cancer : results of a meta-analysis of randomized clinical trials" 51 : 91-101, 2014

      10 McBean AM, "The underuse of screening services among elderly women with diabetes" 30 : 1466-1472, 2007

      1 Pearson-Stuttard J, "Worldwide burden of cancer attributable to diabetes and high body-mass index : a comparative risk assessment" 6 : e6-e15, 2018

      2 Burstein HJ, "Use of the peroxisome proliferator-activated receptor(PPAR)gamma ligand troglitazone as treatment for refractory breast cancer : a phase II study" 79 : 391-397, 2003

      3 Noto H, "Unfolding link between diabetes and cancer" 9 : 473-474, 2018

      4 Yu F, "Type 2 diabetes mellitus and risk of colorectal adenoma : a meta-analysis of observational studies" 16 : 642-, 2016

      5 Shlomai G, "Type 2 diabetes mellitus and cancer : the role of pharmacotherapy" 34 : 4261-4269, 2016

      6 Tsilidis KK, "Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies" 350 : g7607-, 2015

      7 Lim D, "Trends in major cancer mortality in Korea, 1983-2012, with a joinpoint analysis" 39 : 939-946, 2015

      8 서민아, "Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2013" 대한암학회 48 (48): 1-10, 2016

      9 Monami M, "Thiazolidinediones and cancer : results of a meta-analysis of randomized clinical trials" 51 : 91-101, 2014

      10 McBean AM, "The underuse of screening services among elderly women with diabetes" 30 : 1466-1472, 2007

      11 Greenwood M, "The relation between the cancer and diabetes death-rates" 14 : 83-118, 1914

      12 Ko C, "The need for a multidisciplinary approach to cancer care" 105 : 53-57, 2002

      13 김경진, "Ten-Year Mortality Trends for Adults with and without Diabetes Mellitus in South Korea, 2003 to 2013" 대한당뇨병학회 42 (42): 394-401, 2018

      14 Noto H, "Significantly increased risk of cancer in diabetes mellitus patients : a meta-analysis of epidemiological evidence in Asians and non-Asians" 3 : 24-33, 2012

      15 Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomized controlled trial" 366 : 1279-1289, 2005

      16 Monami M, "Safety issues with glucagon-like peptide-1 receptor agonists(pancreatitis, pancreatic cancer and cholelithiasis) : data from randomized controlled trials" 19 : 1233-1241, 2017

      17 Tang H, "SGLT2 inhibitors and risk of cancer in type 2 diabetes : a systematic review and meta-analysis of randomized controlled trials" 60 : 1862-1872, 2017

      18 강유미, "Role of NO/VASP Signaling Pathway against Obesity- Related Inflammation and Insulin Resistance" 대한당뇨병학회 41 (41): 89-95, 2017

      19 Overbeek JA, "Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis" 34 : e3004-, 2018

      20 진상만, "Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study" 대한의학회 29 (29): 238-242, 2014

      21 Anothaisintawee T, "Risk factors of breast cancer : a systematic review and meta-analysis" 25 : 368-387, 2013

      22 Heckman-Stoddard BM, "Repurposing metformin for the prevention of cancer and cancer recurrence" 60 : 1639-1647, 2017

      23 Lipscombe LL, "Reduced screening mammography among women with diabetes" 165 : 2090-2095, 2005

      24 Huang Y, "Prediabetes and the risk of cancer : a meta-analysis" 57 : 2261-2269, 2014

      25 Lewis JD, "Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes" 314 : 265-277, 2015

      26 Mehtälä J, "Pioglitazone use and risk of bladder cancer : a systematic literature review and meta-analysis of observational studies" 10 : 24-36, 2018

      27 Ryder RE, "Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit" 32 : 305-313, 2015

      28 Yee LD, "Pilot study of rosiglitazone therapy in women with breast cancer : effects of short-term therapy on tumor tissue and serum markers" 13 : 246-252, 2007

      29 Wu L, "Pharmacologic therapy of diabetes and overall cancer risk and mortality : a meta-analysis of 265 studies" 5 : 10147-, 2015

      30 Calle EE, "Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms" 4 : 579-591, 2004

      31 Pollak M, "Overcoming drug development bottlenecks with repurposing : repurposing biguanides to target energy metabolism for cancer treatment" 20 : 591-593, 2014

      32 Ricart W, "No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance" 9 : 631-636, 2001

      33 Lee JH, "New-onset diabetes patients need pancreatic cancer screening?" 46 : e58-e61, 2012

      34 Kang YM, "Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013" 15 : 131-, 2016

      35 Thakkar B, "Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies" 62 : 922-934, 2013

      36 Gandini S, "Metformin and cancer risk and mortality : a systematic review and meta-analysis taking into account biases and confounders" 7 : 867-885, 2014

      37 Barone BB, "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and meta-analysis" 300 : 2754-2764, 2008

      38 van de Poll-Franse LV, "Less aggressive treatment and worse overall survival in cancer patients with diabetes : a large population based analysis" 120 : 1986-1992, 2007

      39 서성환, "Korean Type 2 Diabetes Patients have Multiple Adenomatous Polyps Compared to Non-diabetic Controls" 대한의학회 26 (26): 1196-1200, 2011

      40 Sciacca L, "Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling" 53 : 1743-1753, 2010

      41 Renehan AG, "Insulin analogues and cancer risk : the emergence of second-generation studies" 55 : 7-9, 2012

      42 Zhang Z, "Incretin-based agents in type 2 diabetic patients at cardiovascular risk : compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes" 16 : 31-, 2017

      43 Sommerfeld MR, "In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites" 5 : e9540-, 2010

      44 Cho NH, "IDF Diabetes Atlas : global estimates of diabetes prevalence for 2017 and projections for 2045" 138 : 271-281, 2018

      45 류태영, "Hyperglycemia as a Risk Factor for Cancer Progression" 대한당뇨병학회 38 (38): 330-336, 2014

      46 Barclay AW, "Glycemic index, glycemic load, and chronic disease risk : a meta-analysis of observational studies" 87 : 627-637, 2008

      47 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017" 392 : 1789-1858, 2018

      48 GBD 2017 Causes of Death Collaborators, "Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017 : a systematic analysis for the Global Burden of Disease Study 2017" 392 : 1736-1788, 2018

      49 Arnold M, "Global burden of cancer attributable to high body-mass index in 2012 : a population-based study" 16 : 36-46, 2015

      50 Tancredi M, "Excess mortality among persons with type 2 diabetes" 373 : 1720-1732, 2015

      51 Sacerdote C, "Epidemiological dimensions of the association between type 2 diabetes and cancer : a review of observational studies" 143 : 369-377, 2018

      52 Pasello G, "Effects of sulfonylureas on tumor growth : a review of the literature" 18 : 1118-1125, 2013

      53 Liu X, "Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK" 111 : E435-E444, 2014

      54 Pinto LC, "Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis : a meta-analysis with trial sequential analysis" 8 : 782-, 2018

      55 Chen L, "Diabetes treatments and risks of adverse breast cancer outcomes among early-stage breast cancer patients : a SEER-medicare analysis" 77 : 6033-6041, 2017

      56 Coughlin SS, "Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults" 159 : 1160-1167, 2004

      57 Gordon-Dseagu VL, "Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease : evidence from the Health Survey for England and Scottish Health Survey cohorts" 28 : 791-797, 2014

      58 Hua F, "Diabetes and cancer, common threads and missing links" 374 : 54-61, 2016

      59 Renehan AG, "Diabetes and cancer(2) : evaluating the impact of diabetes on mortality in patients with cancer" 55 : 1619-1632, 2012

      60 Cignarelli A, "Diabetes and cancer : pathophysiological fundamentals of a ‘dangerous affair’" 143 : 378-388, 2018

      61 Giovannucci E, "Diabetes and cancer : a consensus report" 33 : 1674-1685, 2010

      62 Badrick E, "Diabetes and cancer : 5 years into the recent controversy" 50 : 2119-2125, 2014

      63 서성환, "Diabetes and Cancer: Is Diabetes Causally Related to Cancer?" 대한당뇨병학회 35 (35): 193-198, 2011

      64 Sen Li, "Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study" 대한당뇨병학회 43 (43): 319-341, 2019

      65 ORIGIN Trial Investigators, "Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids(ORIGINALE)" 39 : 709-716, 2016

      66 쿰반월터척, "Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007-2009" 한국역학회 39 : 1-8, 2017

      67 Harding JL, "Cancer risk among people with type 1 and type 2 diabetes : disentangling true associations, detection bias, and reverse causation" 38 : 264-270, 2015

      68 Carstensen B, "Cancer incidence in persons with type 1 diabetes : a five-country study of 9, 000 cancers in type 1 diabetic individuals" 59 : 980-988, 2016

      69 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015" 대한암학회 50 (50): 303-316, 2018

      70 Starup-Linde J, "CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants. A systematic review and a meta-analysis" 8 : 296-332, 2013

      71 Byers T, "Body fatness as a cause of cancer : epidemiologic clues to biologic mechanisms" 22 : R125-R134, 2015

      72 ORIGIN Trial Investigators, "Basal insulin and cardiovascular and other outcomes in dysglycemia" 367 : 319-328, 2012

      73 Chen Y, "Association between type 2 diabetes and risk of cancer mortality : a pooled analysis of over 771, 000 individuals in the Asia Cohort Consortium" 60 : 1022-1032, 2017

      74 Xu J, "Association between markers of glucose metabolism and risk of colorectal cancer" 6 : e011430-, 2016

      75 Ptaszynska A, "Assessing bladder cancer risk in type 2 diabetes clinical trials : the dapagliflozin drug development program as a ‘case study’" 6 : 357-375, 2015

      76 Tseng CH, "An updated review on cancer risk associated with incretin mimetics and enhancers" 33 : 67-124, 2015

      77 Kyrgiou M, "Adiposity and cancer at major anatomical sites : umbrella review of the literature" 356 : j477-, 2017

      78 Terzolo M, "Acromegaly is associated with increased cancer risk : a survey in Italy" 24 : 495-504, 2017

      79 Romera I, "A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes" 10 : 5-19, 2019

      80 Kulke MH, "A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer" 8 : 395-399, 2002

      81 Lim SS, "A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010" 380 : 2224-2260, 2012

      82 American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. 2019" 42 (42): S90-S102, 2019

      83 American Diabetes Association, "4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes. 2019" 42 (42): S34-S45, 2019

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2017-12-01 평가 SCIE 등재 (기타) KCI등재
      2011-05-30 학술지명변경 한글명 : KOREAN DIABETES JOURNAL -> Diabetes and Metabolism Journal KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2006-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2005-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2004-01-01 평가 등재후보학술지 유지 (등재후보1차) KCI등재후보
      2003-01-01 평가 등재후보학술지 유지 (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 유지 (등재후보1차) KCI등재후보
      2000-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.55 0.55 0.55
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.49 0.5 1.018 0.21
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼